KRT17 and urinary bladder cancer: KRT17 expression was significantly high in pT1 (11.5-fold, p = 2.7 x 10-7), pT2 and higher stages (15.0-fold, p = 4.0 x 10-4), G2 (1.4-fold, p = 0.022) and G3 bladder cancer (6.7-fold, p = 1.8 x 10-6), which was consistent with the expression of SLC2A1 and GPRC5A (Figure 3C, 3F).